Wallrabenstein, T.; Oseledchyk, A.; Daetwyler, E.; Rochlitz, C.; Vetter, M.
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer. Cancers 2023, 15, 4953.
https://doi.org/10.3390/cancers15204953
AMA Style
Wallrabenstein T, Oseledchyk A, Daetwyler E, Rochlitz C, Vetter M.
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer. Cancers. 2023; 15(20):4953.
https://doi.org/10.3390/cancers15204953
Chicago/Turabian Style
Wallrabenstein, Till, Anton Oseledchyk, Eveline Daetwyler, Christoph Rochlitz, and Marcus Vetter.
2023. "Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer" Cancers 15, no. 20: 4953.
https://doi.org/10.3390/cancers15204953
APA Style
Wallrabenstein, T., Oseledchyk, A., Daetwyler, E., Rochlitz, C., & Vetter, M.
(2023). Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer. Cancers, 15(20), 4953.
https://doi.org/10.3390/cancers15204953